Search NASA⌕ Search

Engineering topics

Kramer, Frank

Publications and source records attributed to Kramer, Frank.

Developing IVHM Requirements for Aerospace Systems

The term Integrated Vehicle Health Management (IVHM) describes a set of capabilities that enable sustainable and safe operation of components and subsystems within aerospace platforms. However, very little guidance exists for the systems engineering aspects of design with IVHM in mind. It is probably because of this that designers have to use knowledge picked up exclusively by experience rather than by established process. This motivated a group of leading IVHM practitioners within the aerospace industry under the aegis of SAE's HM-1 technical committee to author a document that hopes to give working engineers and program managers clear guidance on all the elements of IVHM that they need to consider before designing a system. This proposed recommended practice (ARP6883 [1]) will describe all the steps of requirements generation and management as it applies to IVHM systems, and demonstrate these with a "real-world" example related to designing a landing gear system. The team hopes that this paper and presentation will help start a dialog with the larger aerospace community and that the feedback can be used to improve the ARP and subsequently the practice of IVHM from a systems engineering point-of-view.

IVHM↗

A Gene Expression Signature for Chemoradiosensitivity of Colorectal Cancer Cells

Purpose: The standard treatment of patients with locally advanced rectal cancers comprises preoperative 5-fluorouracil-based chemoradiotherapy followed by standardized surgery. However, tumor response to multimodal treatment has varied greatly, ranging from complete resistance to complete pathologic regression. The prediction of the response is, therefore, an important clinical need. Methods and Materials: To establish in vitro models for studying the molecular basis of this heterogeneous tumor response, we exposed 12 colorectal cancer cell lines to 3 {mu}M of 5-fluorouracil and 2 Gy of radiation. The differences in treatment sensitivity were then correlated with the pretherapeutic gene expression profiles of these cell lines. Results: We observed a heterogeneous response, with surviving fractions ranging from 0.28 to 0.81, closely recapitulating clinical reality. Using a linear model analysis, we identified 4,796 features whose expression levels correlated significantly with the sensitivity to chemoradiotherapy (Q <.05), including many genes involved in the mitogen-activated protein kinase signaling pathway or cell cycle genes. These data have suggested a potential relevance of the insulin and Wnt signaling pathways for treatment response, and we identified STAT3, RASSF1, DOK3, and ERBB2 as potential therapeutic targets. The microarray measurements were independently validated for a subset of these genes using real-time polymerase chain reactions. Conclusion: We are the first to report a gene expression signature for the in vitro chemoradiosensitivity of colorectal cancer cells. We anticipate that this analysis will unveil molecular biomarkers predictive of the response of rectal cancers to chemoradiotherapy and enable the identification of genes that could serve as targets to sensitize a priori resistant primary tumors.

62 RADIOLOGY AND NUCLEAR MEDICINE↗